ESSA Pharma Inc. Proxy Solicitation Filing
| Field | Detail |
|---|---|
| Company | Essa Pharma Inc. |
| Form Type | DEFA14A |
| Filed Date | Jul 31, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, shareholder-meeting
TL;DR
ESSA Pharma filed proxy docs, shareholders vote soon.
AI Summary
ESSA Pharma Inc. filed a DEFA14A on July 31, 2025, related to its solicitation of proxies. The filing indicates that the company is seeking shareholder approval for matters to be discussed at its upcoming annual general meeting. Specific details regarding the proposals or the date of the meeting are not provided in this excerpt.
Why It Matters
This filing is important for shareholders as it outlines the proposals they will be asked to vote on, impacting corporate governance and future company decisions.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement and does not contain information that inherently increases the company's risk profile.
Key Players & Entities
- ESSA Pharma Inc. (company) — Registrant
- July 31, 2025 (date) — Date of Report
- Vancouver, British Columbia, Canada (location) — Principal Executive Offices
FAQ
What is the purpose of this DEFA14A filing?
The purpose of this DEFA14A filing is to solicit proxies from shareholders for matters to be voted on at the company's annual general meeting.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is July 31, 2025.
Where are ESSA Pharma Inc.'s principal executive offices located?
ESSA Pharma Inc.'s principal executive offices are located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada.
What is the company's fiscal year end?
The company's fiscal year end is September 30 (0930).
What is the SEC file number for ESSA Pharma Inc.?
The SEC file number for ESSA Pharma Inc. is 001-37410.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on July 31, 2025 regarding ESSA Pharma Inc..